

Primary Prevention of Cardiovascular Disease

We compared the health-adjusted life expectancy, caregiving needs, medical costs, and workforce participation between a person at high risk for cardiovascular disease (CVD) and a comparable person from the US general population. The differences between the two represent the unmet need and define the opportunity for innovation in the primary prevention of CVD.



PATIENT OPPORTUNITY

Increase health-adjusted life expectancy

1.5 discounted health-adjusted life years to recover

\$650K-\$2.1M

value from improved health per person at high risk for CVD



CAREGIVER OPPORTUNITY

Free up time spent providing care

95 hours of disease-related caregiving time to free up

\$1.3K

CVD-related caregiving time to free up



HEALTH SYSTEM OPPORTUNITY

Reduce disease-related medical costs

\$36K net medical cost savings after accounting for added costs of living longer

\$90K

CVD-related medical costs to avoid



ECONOMIC OPPORTUNITY

Restore workforce productivity

0.2 full-time-equivalent years of productivity to recover

\$23K

additional paid labor production

ANALYTIC APPROACH AND CONTEXT

The report is about the broader progress that innovation in the primary prevention of CVD could provide, not about the reimbursement or pricing of specific therapeutics. The analysis compares estimated outcomes for a person at high risk for CVD (i.e., approximate 20% probability of a cardiovascular event within 10 years) with an LDL cholesterol level of at least 90 mg/dL while receiving a generic lipid-lowering therapy to a comparable person in the general US population. Gaps in health-adjusted life expectancy, caregiving, medical costs, and workforce participation were monetized and discounted at a 3% discount rate. All monetary estimates are in 2025 US dollars. Importantly, societal value estimates by stakeholder group may not be additive, this not a comprehensive assessment of all societal impacts of CVD, and the interpretation of caregiver time findings are subject to important data limitations. Read the full report for more information.

AUTHOR:

Melanie D. Whittington, PhD, MS
Managing Director and Head
Leerink Center for Pharmacoeconomics

Disclosures

The Center for Pharmacoeconomics (“CPE”) is a division of MEDACorp LLC (“MEDACorp”). CPE is committed to advancing the understanding and evaluating the economic and societal benefits of healthcare treatments in the United States. Through its thought leadership, evaluations, and advisory services, CPE supports decisions intended to improve societal outcomes. MEDACorp, an affiliate of Leerink Partners LLC (“Leerink Partners”), maintains a global network of independent healthcare professionals providing industry and market insights to Leerink Partners and its clients. The information provided by the Center for Pharmacoeconomics is intended for the sole use of the recipient, is for informational purposes only, and does not constitute investment or other advice or a recommendation or offer to buy or sell any security, product, or service. The information has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and any opinions and information contained herein are as of the date of this material, and MEDACorp does not undertake any obligation to update them. This document may not be reproduced, edited, or circulated without the express written consent of MEDACorp.